Zimmer Biomet's worldwide knee sales plummet 46.8% in Q2, hitting $374M

Spinal Tech

Zimmer Biomet reported sharp sales declines across all product categories in the second quarter.

Eight takeaways from the company's latest earnings report:

1. Zimmer's net sales were $1.23 billion in the second quarter, down 38.3 percent from the same period in 2019.

2. Zimmer recorded a net loss of $206.6 million in the second quarter, with adjusted net earnings of $10.2 million. Second-quarter diluted loss per share was $1. Diluted earnings per share dropped 97.4 percent year over year, hitting $0.05.

3. In the Americas, net sales from knee products were $221 million, down 46.7 percent year over year. Total net sales from knees were down 46.8 percent year over year at $374.2 million.

4. Hip product net sales in the Americas were $170.7 million, representing a milder year-over-year decline of 32.6 percent. The global decrease for hips was 31.1 percent, leaving Zimmer with $329.7 million in overall net sales for that category in the second quarter.

5. The sports medicine, extremities and trauma category saw a 29.2 percent year-over-year drop in net sales, ending the second quarter with $252.6 million. Net sales for dental, spine and craniomaxillofacial and thoracic products were down nearly 38 percent at $182.5 million.

6. In the second quarter, Zimmer used $52.8 million of net cash in operating activities. Zimmer ended the quarter with $713.4 million in cash and cash equivalents on its balance sheet.

7. The company paid $49.6 million in dividends and declared a dividend of $0.24 per share in the second quarter, when it also refinanced $1.5 billion in debt due April 1. By renegotiating terms of its $1.5 billion revolver, Zimmer secured an additional $1 billion credit facility with no outstanding borrowings.

8. COVID-19 caused a worldwide decline in elective procedure volumes, hurting Zimmer Biomet's performance in the three months ended June 30 and leading the company to pull its full-year guidance. To position itself for long-term growth amid lingering fallout from the pandemic, Zimmer is "investing aggressively" in primary growth initiatives, as well as research and development programs, according to President and CEO Bryan Hanson.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers